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ickle cell disease (SCD) is an inherited disease resulted due to a single mutation in beta globin gene. It 
changes normal red blood cells into sickle-shaped cells, just rendering their ability to carry oxygen to 
tissues and cells.  SCD involves many fatal clinical complications including very painful vaso-occlusive 
crisis (VOC), the later caused by sickled erythrocytes-mediated ischemic tissue injury and obstruction of blood 
flow that leads. Pain in VOC is caused by hypoxia, acidosis, fever, infections, dehydration, obstructive sleep 
apnea, abrupt changes in weather (hot / cold), menstruation and pregnancy etc. Pain in VOC is very severe and 
is associated with many other life-threatening clinical complications. Therefore, it is needed be managed as early 
as possible, otherwise persistent pain can weaken patients physically and psychologically. There are no specific 
laboratory indicators for VOC and diagnosis is made on the basis of history and physical examination. We 
formulated clinical guidelines for the management of acute painful crisis (VOC) in sickle cell patients based upon 
updated published medical literature, in addition to our experience of treating sickle cell patients King Abdulaziz 
National Guards Hospital, Al-Ahsa, Saudi Arabia, which is its application to an Asian publication. This report 
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Sickle cell disease (SCD) is an autosomal recessive 
disorder caused by a single gene mutation that 
transforms normal red blood cells into sickle-shaped 
cells [1] It leads to many fatal clinical complications 
including vaso-occlusive crisis (VOC) [2]. The sickled 
erythrocytes cause ischemic tissue injury by obstructing 
blood flow that leads to VOC [3]. The reduction in blood 
flow due to sickle-shaped erythrocytes causes hypoxia 
and acidosis that promotes the process of sickle-cell 
formation and ischemic tissue injury.  
Intensity and duration of VOC varies not only between 
different patients but even in same patient during 
different episodes of VOC [4]. Pain in VOC is caused by 
hypoxia, acidosis, fever, infections, dehydration, 
obstructive sleep apnea, abrupt changes in weather (hot 
/ cold), menstruation and pregnancy [3]. Abdominal pain 
and pain in bones like in back, extremities and swelling 
of finger and toe joints (dactylitis or hand-foot syndrome) 
are mostly experienced due to VOC [5]. The bone pain 
is the most common manifestation and may be 
accompanied by inflammation, redness, warmth and low 
fever. Bone pain may be symmetrical (affecting the 
similar joints on left and right side of the body), 
asymmetrical (pain affecting bone/joint of one side of the 
body) or migratory (pain spreading from one joint to the 
other).  Dactylitis is more common in SCD patients with 
age of 3 years and below while older patients present 
with abdominal and back pain [6]. Although abdominal 
pain, if present in SCD children, is mild, but it may be 
accompanied with other manifestations like pelvic 
inflammatory disease, urinary tract infection, 
cholecystitis, pancreatitis, appendicitis, splenic 
sequestration, liver sequestration, pneumonia and chest 
crisis and it is necessary to rule-out these complications 
[4]. Moreover, in case of severe painful crisis, patients 
may experience acute chest syndrome due to sickling in 
the small blood vessels of the lungs [7, 8]. It may involve 
the most devastating central nervous system 
complications including overt stroke in 10% SCD 
children and silent cerebral infarcts in about 35% SCD 
patients [9]. CNS manifestations lead to many 
neuropsychological complications. Therefore, it is 
necessary to rule out these complications in SCD 
children presented with painful VOC.  
Due to its severity and/or its association with many 
other serious clinical manifestations, treatment for pain 
in VOC should started as soon as diagnosis is made, 
otherwise persistence of pain can weaken patients 
physically and psychologically [3, 4]. There are no 
specific laboratory features indicative of VOC and 
therefore diagnosis is merely made on the basis of 
history and physical examination [10, 11]. At King 
Abdulaziz National Guards Hospital Al-Ahsa, we 
developed some clinical guidelines for the management 
of acute painful crisis (VOC) in sickle cell patients. These 
guidelines are based upon our experience of managing 
VOC in sickle cell patients and other published 
guidelines from prestigious health centers in North 
America. Below we are presenting an outline of these 
guidelines. 
Methods 
Literature Search and Selection Criteria:  We utilized 
different databases like PubMed (NCBI), Scopus, 
Google scholar and google to search the articles and 
published material related to our review paper. Different 
keywords utilized to search data were “Sickle cell 
disease, Vaso-Occlusive Crisis, Acute Pain, 
management and Pediatric”.  Original peer / reviewed 
articles, review articles, meta-analysis and clinical trials 
were considered for this review was addressing clinical 
management of acute pain in SCD patients with VOC.  
Case studies were excluded. 
Discussion 
SCD patient management in ER (Emergency 
Department) (Grade C) [12] 
ER assessment of SCD patients with fever: If SCD 
patient has consistent fever of 38.5 °C, transfer patient 
on ER bed and follow “Clinical Guidelines for Fever 
Management”.  Carry out a thorough assessment of the 
patient after administration of antibiotics (Appendix 1).  
ER assessment of SCD patients without fever: 
Transfer SCD patient without fever to a BED at the 
earliest. Take brief history and carry out physical 
examination concurrently with measures as given in 
Table 1. If child is having fever, respiratory illness or/and 
fever, go for x-ray of the chest as well as monitor his/her 
oxygen (O2) saturation. If patient is complaining of 
severe respiratory distress, request for arterial blood gas 
(ABC) level testing additionally [13, 14].  
History Physical examination Laboratory tests 
1. Nature of pain 
2. Duration 
3. Location 
4. Severity of pain 
(See Pain 
Assessment Policy) 
5. Compare pain with 
previous episodes 
of the crisis 












2. Check size of the 
spleen 
3. Examine patient’s 
neurological system. 
4. Check if patient has 
jaundice. 
5. Look for signs of 
infection. 
1. Request complete 
blood counts 
(CBC), differential 
blood cell counts 
and reticulocyte 
count. 
2. Go for typing of 
blood groups and 
request to 
crossmatch blood 
in case if the child 
is in severe pain or 
if his/her 
hemoglobin level is 
15 grams per liter 





normal, it is an 
indication of bone 
marrow 
suppression. 
3. If there are clinical 
indications, go for 
urine analysis and 
electrolytes. 
4. If child is 
experiencing 
abdominal pain, go 
for liver function 
test and amylase 
testing. 
Table 1: SCD patient management in ER (Emergency Department) 
If you find patient febrile (feverish), dehydrated or 
complaining of moderate to severe pain, insert an 
intravenous (I.V.) catheter. 
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Page and inform the Hematology consult service if 
available. Hematology consultant should examine all 
SCD patients who are have serious condition and should 
arrange their proper follow-up. Following are criteria to 
see if any patient has serious illness:  
• Patients in shock (i.e. life-threatening medical 
condition) with symptoms are very low blood 
pressure etc. 
• Patients with aplastic crisis, acute splenic 
sequestration crisis, sepsis, meningitis, stroke 
etc.  
• Decompensating patients, for example, 
patients who progressing into chest crisis etc. 
• Patients showing oxygen saturation less than 
90% while breathing room air. 
In case of fever, acute chest crisis, gallstones etc., 
please follow other guidelines of “Sickle Cell 
Management Protocols” specific to these complications 
[14-16]. 
Pain management through Medication in Emergency 
department (ER) 
Please adopt protocols provided in table 2 to manage 
pain, depending upon pain severity [17, 18]: 
Adjunct pain relief management: For mild, moderate 
and severe pain, Acetaminophen 75 mg/kg/day PO 
(maximum dose 4g/day) and an non-steroidal anti-
inflammatory drug (NSAID) can be given as adjunct pain 
relief medication along with morphine, unless there are 
any contraindications to their use. Before using NSAIDs, 
assess renal function and consult with pharmacist if you 
find results abnormal [17]. 
Recommended NSAIDs include: 
Ibuprofen: For children 6 months-12 years old: 5-10 
mg/kg/dose PO q6-8h (orally, every 6-8 hours); Not to 
exceed 40 mg/kg/day or 2400 mg/day.  
Naproxen: 10-20 mg/kg/day PO divided BID (orally, 
twice daily); Not to exceed 1 g/day). 
Ketorolac: 0.5 mg/kg/dose intravenous (I.V.) q6-8h 
(every 6-8 hours); Not to exceed 15 mg/dose), maximum 
for 48 hours and after that change switch to ibuprofen or 
naproxen. 
Pain management for Indoor patients [18-20]: 
You need to admit patient if pain is inadequately 
controlled with oral analgesics or in case of other 
complications such as fever, dehydration etc.  
Patients should be admitted to hospital ward only under 
General Pediatrics Service. 
Pain management through Medication for outdoor 
patients [18, 19] 
• Prescribe oral morphine dose that adequately 
relieved pain as stated in 2.1.7 (don’t exceed 15 
mg/dose). In case patient needed higher doses 
during previous ER visits for painful VOC, 
consult patient chart and hematology service. 




Pain medication Comments 
Mild to moderate 
pain 
Morphine:  
0.3-0.5 mg/kg/dose PO 
(by mouth) G4H (every 
four hours) PRN (as 
needed). The maximum 




PO Q4H PRN. Do not 
exceed 4mg/dose. 
Induce patients to drink water. 
In case pain is not relieved 
adequately in half to one hour, 
switch to guidelines for 
moderate to severe pain 
provided below. 
In case of adequate pain relief 
and if there are no other acute 
complications, you may 
discharge the patients and 
prescribe oral analgesics. 
Please consult guidelines for 
“Outpatient Management” for 
this purpose.  
Moderate to severe 
pain 
Morphine: 
Intravenous (I.V.) bolus 





I.V. bolus of 0.015-0.02 
mg/kg/dose (max dose 1 
mg) or PO bolus of 0.04-
0.08 mg/kg/dose (max 
dose: 4 mg) 
You may consider giving 
intravenous bolus again after 
one hour or later in case if pain 
is not relieved adequately.  
 
In case a patient needs more 
than 2 intermittent I.V. doses of 
opioid, he/she must be 
admitted (please consult 
guidelines for inpatient 
management) and an opioid 
infusion should be given for 
severe pain (as stated below). 
In case if pain is relieved 
adequately for two hours with 
1-2 doses of intermittent 
intravenous opioid, you need 
to change to equivalent oral 
opioid dose. You may 
discharge the patient provided 
pain is controlled on oral opioid 
and patient is tolerating oral 
fluids. 
 
Please give intravenous fluids 
to all patients with moderate to 
severe pain. It should consist 
of a 10mL/kg bolus of saline, 
followed by 1.5 times the 
maintenance intravenous rate 
of 5% dextrose in 0.9% sodium 
chloride solution. 
Severe Pain Morphine:  
I.V. bolus of 0.05-0.1 
mg/kg/dose (do not 
exceed 7.5 mg/dose) 
followed by morphine 
continuous I.V. infusion 
40 micrograms /kg /hour 
Additionally, patient can 
be given boluses of 
morphine (0.05 mg/kg) 
q1-2h (every 1-2 hours) 
PRN for breakthrough 
pain (sudden and brief 
flare-up of pain). 
OR 
Hydromorphone: 
I.V. bolus of 0.015-
0.02mg/kg/dose (don’t 
exceed 1 mg/dose) 
followed by 
Hydromorphone 
continuous I.V. infusion 
Additionally, patient can 




2h PRN for breakthrough 
pain 
To all patients in moderate to 
severe pain, administer fluids 
intravenously, as: First give a 
bolus of saline (10 milliliter per 
kilogram of body weight), after 
that administer 1.5 times of the 
maintenance I.V. rate, with 
dextrose 5% in sodium 
chloride 0.9% solution. 
Table 2: Pain management through Medication in Emergency 
department [18].
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• For mild, moderate and severe pain, 
Acetaminophen 75 mg/kg/day PO (maximum 
dose 4g/day) AND a non-steroidal anti-
inflammatory drug (NSAID) can be given as 
adjunct pain relief medication along with 
morphine, unless there are any 
contraindications to their use. Please consult 
table 3 for dosing. 
Patients are needed to be observed closely for signs of 
deterioration and are required to be monitored 
continuously with cardiac and oxygen (O2) saturation, for 
vital signs every four hours, for fluid input and output as 
well as daily weight.  It is required to carry out 
assessment of patient’s comfort level every 4 hours. This 
assessment is also required before as well as after every 
treatment provided for pain management and even after 






Morphine 0.3-0.5 mg/kg/dose 
PO (by mouth) Q4H 
(every 4 hours) PRN 
(as needed. 
Don’t exceed 15 
mg/dose. 
In case patient needed higher 
doses during previous ER visits 
for painful VOC, consult patient 
chart and hematology service. 
Reevaluate the patient if in not 











unless there are 
any 
contraindications 





75 mg/kg/day PO  








Before using NSAIDs, assess 
renal function and consult with 
pharmacist if you find results 
abnormal 
Ibuprofen For patients aged 6 
months to 12 years: 
5-10 mg/kg/dose PO 
q6-8h (by mouth, 
every 6-8 hours) 
Don’t exceed 40 
mg/kg/day or 2400 
mg/day 
None 
Naproxen 10-20 mg/kg/day PO  
divided bid (orally, 
twice daily) 
Don’t exceed 1 
g/day. 
None 
Ketorolac 0.5 mg/kg/dose 
intravenous q6-8h 
(every 6-8 hours). 
Don’t exceed 15 
mg/dose. 
Use it for 48 hours 




Table 3: Drug dosing for pain management (outdoor patients). 
If patient is hospitalized with chest and back pain, refer 
to him/her to Physiotherapy. It is recommended for 
physiotherapist to determine if incentive spirometry (10 
breaths every 1-2 hours while awake) is appropriate for 
older children (8 years or older). For younger children, 
physiotherapist should motivate them use bubbles for 
deep breathing. The physiotherapist should also 
encourage walking without any support (ambulation) and 
any other activities keeping in consideration patient’s 
tolerance. Per recommendations of physiotherapists, 
other health professionals involved should also promote 
child’s mobility [13]. 
Referral of the patient to Physiotherapy is required if 
he/she is showing significant decrease in mobility or 
restricted joint movement. 
To improve patient comfort level, non-pharmacological 
interventions such as massage, heating pads, warm 
baths, and other such methods should be utilized. It is 
advisable for “Child Life representative” to recommend 
structured daily activity for the patient. Use of Imagery 
and distraction prove to be helpful. 
In case if pain is not relieved even after using 
analgesics or if any pain-related are encountered, 
consultation with Pain Management Team is highly 
recommended. 
Give patient boluses of morphine intravenously for 
breakthrough pain (consult table 4 for exact doses).  
After maintaining effective dose for 24 hours, gradually 
decrease dose by up to 20 micrograms/kg/hour in next 
24 hours. If patient is stable, continuous intravenous 
morphine may be replaced by an equal dose of long-
acting oral morphine (consult table 4 for exact doses).  
Step-down therapy: For those patients who are 
comfortable, it is recommended to change to oral 
analgesics (morphine 0.3-0.5 mg/kg/dose orally every 4 
hours as needed (PO, q4h, PRN prn). Don’t exceed 15 
mg/dose (consult table 4 for exact doses). 
For mild, moderate and severe pain, Acetaminophen 
75 mg/kg/day PO (maximum dose 4g/day) AND a non-
steroidal anti-inflammatory drug (NSAID) can be given 
as adjunct pain relief medication along with morphine, 
unless there are any contraindications to their use 
(consult table 4 for exact doses). 
In case of pain persisting for more than 24-48 hours in 
patients older than 6 years of age, using Patient 
Controlled Analgesia (PCA) pump is recommended [21-
23]. Similarly, utilize a PCA pump for any child already 
treated with a PCA pump or for children who did not 
achieve adequate analgesia. A PCA pump has capability 
to deliver a continuous infusion as well as intravenous 
boluses of morphine or any other medication per patient 
need and a required dose and interval of medication can 
be pre-programmed by the prescriber (physician) and 
therefore chances of overdosing are negligible if PCA 
pump is used. Please contact (through pager) the Pain 
Management Team to get PCA pump and they can set it 
at its basal rate, bolus rate, and lockout time. It is 
mandatory to observe patients carefully for opioid toxicity 
when patients are on morphine. The indications of opioid 
toxicity include hypotension, bradycardia, drowsiness, 
coma, pinpoint pupils, cold clammy skin, and 
hypoventilation. It is required to regularly monitor and 
record patient's heart rate, respiratory rate and oxygen 
saturation while observing patient for opioid toxicity.  
Use of stool softeners: If the patient does not have 
diarrhea, it is required to administer him/her a stool 
softener such as Docusate Sodium (5 mg/kg/day for 
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children). You administer it in three equal doses or as a 
single daily dose.  Adult daily dose is 100-200 mg. 
Name of drug Drug Dose Comments 











If patient is stable, continuous intravenous 
morphine may be replaced by an equal 








• Intravenous morphine (40 
micrograms /kg/hour) should be 
continued.  
• In case if pain is not relieved 
adequately, adjust the dose every 8 
hours (q8h) by increasing 10-20 
micrograms/kg/hour. Don’t exceed 
the dose of 100 micrograms/kg/hour. 
• In case of breakthrough pain, it is 
permissible to give boluses of 0.05 
mg/kg morphine every 1-2 hours 
intravenously as needed (q1-2h, IV 
PRN). 
• After maintaining effective dose for 
24 hours, gradually decrease dose 
by up to 20 micrograms/kg/hour in 
next 24 hours. 
Acetaminophen  
 









Along with Acetaminophen, non-steroidal anti-inflammatory drugs ((NSAIDs) as 
adjunct pain relief medication along with morphine, unless there are any 




 Before using NSAIDs, assess renal 
function and consult with pharmacist if 
you find results abnormal 
Ibuprofen For patients 
aged 6 months 
to 12 years: 5-
10 mg/kg/dose 





























Table 4: Pain management through Medication for indoor patients 
Use of antihistamines: For patients with pruritus, 
prescribe antihistamines PRN (as needed). 
Hydration: For hydrating patients, fluids should be 
continually given intravenously or orally at 1-1.5 times 
the maintenance rate. Fluid maintenance rate can be 
calculated using specific charts and formulas provided in 
medical literature [24, 25]. 
Oxygen: Systematic use of oxygen is not recommended 
for VOC in sickle cell patients, based upon many studies 
and reports. Nevertheless, SCD children with VOC may 
develop hypoxia that can promote sickling process. 
Accordingly, it is highly recommended to regularly 
monitor oxygen saturation in such patients and if patients 
have indications of hypoxemia, oxygen should be 
provided [26, 27].  
Use of Corticosteroids: For sickle cell patients, 
effectiveness of corticosteroids as an adjunct therapy for 
reducing pain duration is not clear. Therefore, it is 
recommended to avoid using corticosteroids routinely 
unless data from some new clinical trials supports their 
use [27].  
Guidelines foe discharge patients:  
The patients can be discharged in following cases: 
i. If patients are tolerating fluids and medications 
orally. 
ii. If there is adequate pain relief using oral 
medications.  
iii. If all concurrent problems of the patient are 
resolved. 






IV bolus 0.1 mg/kg/dose Max 7.5 mg /dose 
Continues IV 
infusion 
40 mcg/kg/h NA 
IV 
Breakthrough 
0.05 mg/kg QI-2 PRN 
Hydromorphone oral 0.04-0.08 
mg/kg/dose 
Q4h PRN max 
4mg/dose 








0.015 mg/kg 1-2 PRN 
ACETAMINOPHEN Oral 75mg/kg/day Max 4gm /day 




Naproxen Oral 5-10 mg/kg Q 12 (max 1 gm 
/day) 
Ketorolac  0.5mg/kg/dose Q 6-8 (max 
15mg/dose)x48 
hours max 
Table 5: List of drugs for pain management in sickle cell patients with 
route of administration and dosage.    
Conclusion 
Sickle cell disease (SCD) is an familial disorder resulted 
due to a single mutation in beta globin gene. It leads to 
many fatal clinical complications including painful vaso-
occlusive crisis (VOC), requiring acute clinical 
management. VOC pain is caused by hypoxia, acidosis, 
fever, infections, dehydration, obstructive sleep apnea, 
abrupt changes in weather (hot / cold), menstruation and 
pregnancy etc. Pain in VOC is very severe and leads to 
many other life-threatening clinical complications if not 
timely diagnosed and properly treated. Nevertheless, 
there are clear laboratory indicators for VOC. We 
formulated clinical guidelines for the management of 
acute painful crisis (VOC) in sickle cell patients by 
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utilizing published clinical data as well as our experience 
of treating sickle cell patients at a tertiary care hospital in 
Al-Ahsa, Saudi Arabia, as it fits Asian populations better. 
This article describes details of these clinical guidelines 
for management of acute painful vaso-occlusive crisis in 
sickle cell patients. It details practical clinical measures 
to be taken by medical specialists in different fields of 
medicine and their associated healthcare staff to treat 
painful VOC in sickle cell patients. 
 
Pain Pathway for Sickle Cell Disease in Children (Appendix 1) 
Important notes:  
1. Please consider allergies, drug effects, side 
effects and contra-indications prior to 
administration. 
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